Lantern Pharma/$LTRN
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Lantern Pharma
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Ticker
$LTRN
Sector
Primary listing
Employees
24
Headquarters
Website
Lantern Pharma Metrics
BasicAdvanced
$40M
-
-$1.75
1.60
-
Price and volume
Market cap
$40M
Beta
1.6
52-week high
$5.74
52-week low
$2.55
Average daily volume
102K
Financial strength
Current ratio
3.332
Quick ratio
3.06
Total debt to equity
0.98
Profitability
EBITDA (TTM)
-19.654
Management effectiveness
Return on assets (TTM)
-55.99%
Return on equity (TTM)
-104.58%
Valuation
Price to book
4.17
Price to tangible book (TTM)
4.17
Price to free cash flow (TTM)
-2.318
Free cash flow yield (TTM)
-43.14%
Free cash flow per share (TTM)
-1.562
Growth
Earnings per share change (TTM)
-1.18%
3-year earnings per share growth (CAGR)
9.92%
Lantern Pharma News
AllArticlesVideos
2 sub‑$10 AI stocks to outperform Palantir in 2026, according to ChatGPT‑5
Finbold7 days ago
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
Business Wire1 month ago
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantern Pharma stock?
Lantern Pharma (LTRN) has a market cap of $40M as of November 30, 2025.
What is the P/E ratio for Lantern Pharma stock?
The price to earnings (P/E) ratio for Lantern Pharma (LTRN) stock is 0 as of November 30, 2025.
Does Lantern Pharma stock pay dividends?
No, Lantern Pharma (LTRN) stock does not pay dividends to its shareholders as of November 30, 2025.
When is the next Lantern Pharma dividend payment date?
Lantern Pharma (LTRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantern Pharma?
Lantern Pharma (LTRN) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.